Zimmer Biomet’s recent share performance

Zimmer Biomet Holdings (ZBH) has drawn investor attention after a mixed stretch, with the stock edging up about 0.3% over the past day but declining around 2.9% over the past week.

At a share price of US$82.82, Zimmer Biomet’s short term share price momentum has softened, with the 90 day share price return down 15.87%, and the 5 year total shareholder return down 44.33%. This points to fading confidence despite recent daily gains.

If Zimmer Biomet’s recent pullback has you reassessing opportunities in medical technology, it can help to widen your search into healthcare-focused artificial intelligence by reviewing 35 healthcare AI stocks

With shares under pressure over 1 year and 5 years, yet trading below some analyst price targets and certain intrinsic value estimates, is Zimmer Biomet now undervalued, or is the market already pricing in its future growth?

Most Popular Narrative: 15.9% Undervalued

Zimmer Biomet’s most followed narrative pegs fair value at about $98.52, above the last close of $82.82, framing the current share price as materially discounted.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Want to see what sits behind that margin story and revenue mix shift? The narrative highlights measured growth, higher margins, and a very specific future earnings multiple.

Result: Fair Value of $98.52 (UNDERVALUED)

However, there are clear watchpoints, including industry pricing pressure that could squeeze margins, as well as execution risk around integrating acquisitions like Paragon 28 and Monogram.

Next Steps

The mix of risks and rewards around Zimmer Biomet can feel finely balanced, so it makes sense to review the details yourself and decide where you land. If you want a clear snapshot of both sides of the story, take a look at the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Zimmer Biomet is on your radar, do not stop there. Broaden your watchlist with other focused stock ideas sourced directly from the Simply Wall St screener.

• Target potential mispricings by scanning a curated list of companies that currently screen as 46 high quality undervalued stocks
• Prioritise resilience by reviewing 64 resilient stocks with low risk scores that score well on stability and downside protection.
• Hunt for future standouts by checking the screener containing 22 high quality undiscovered gems that combine quality metrics with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.